Device Trial Radar · NCT07091266
SNM vs. HBOT for Refractory IC/BPS
Last checked: Nov 19, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
88
Actual
Start
Feb 1, 2021
Primary completion
Dec 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Shiyan City Renmin HospitalGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Jul 29, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is for people with long-term bladder pain and urinary problems (known as Interstitial Cystitis/Bladder Pain Syndrome or IC/BPS) that have not improved with other treatments. The study compares two different treatments: Sacral Neuromodulation (SNM), which uses an implanted device to send gentle electrical pulses to nerves controlling the bladder, and Hyperbaric Oxygen Therapy (HBOT), where patients breathe pure oxygen in a special chamber. Participants were randomly assigned to one of the two groups to help doctors understand which treatment works better to reduce symptoms and improve quality of life.
Conditions
- Interstitial Cystitis/Bladder Pain Syndrome
- Underactive Bladder
Interventions
Sacral Neuromodulation (SNM)Device
A standardized two-stage implantation protocol was used. In Stage 1, a temporary lead (InterStim 3093, Medtronic) was implanted at the S3 sacral foramen under fluoroscopic guidance. Patients with ≥50% improvement in urinary symptoms over a 7-day test period proceeded to Stage 2, where a permanent neurostimulator (InterStim 3058, Medtronic) was implanted subcutaneously. Stimulation parameters were adjusted (amplitude: 0.5-10 V; frequency: 14 Hz; pulse width: 210 μs) to optimize symptom control.
Hyperbaric Oxygen Therapy (HBOT)Procedure
Patients received two 20-session courses (5 sessions/week) in a hyperbaric chamber at 2.0 atmospheres absolute (ATA). Each session consisted of 60 minutes of 100% oxygen inhalation, bracketed by compression and decompression periods.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Daily Urination FrequencyTime frame: Baseline, 1 Month, 3 Months
- Change in Nocturia FrequencyTime frame: Baseline, 1 Month, 3 Months
- Change from Baseline in Quality of Life Score at 3 MonthsTime frame: Baseline, 3 Months
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renmin Hospital, Hubei University of Medicine
Shiyan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.